Core Insights - Palvella Therapeutics is focused on developing innovative therapies for serious, rare skin diseases and vascular malformations, with a commitment to addressing unmet medical needs [1][7] - The company presented two posters at the 2026 American Academy of Dermatology Annual Meeting, showcasing the QTORIN™ rapamycin platform and a qualitative study on the burden of living with porokeratosis [1][2] Group 1: QTORIN™ Rapamycin - QTORIN™ rapamycin is a single-phase anhydrous gel designed to enhance dermal bioavailability and overcome challenges related to crystallization and stability of rapamycin [1][2] - The Phase 3 SELVA study demonstrated that QTORIN™ rapamycin met its primary endpoint with a statistically significant improvement in the Microcystic Lymphatic Malformation Investigator Global Assessment (p<0.001) [3] - QTORIN™ rapamycin is being developed for multiple conditions, including microcystic lymphatic malformations and cutaneous venous malformations, with no FDA-approved therapies currently available for these indications [4][7] Group 2: Porokeratosis Study - The qualitative study on porokeratosis revealed significant physical and psychosocial burdens faced by patients, including anxiety and limitations in daily activities due to the disease [6][10] - Palvella is developing QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis, with a Phase 2 trial expected to start in the second half of 2026 [6][10] - The study highlighted the urgency for developing targeted therapies for porokeratosis, which affects over 50,000 diagnosed patients in the U.S. [6][10]

Core Insights - Palvella Therapeutics is focused on developing innovative therapies for serious, rare skin diseases and vascular malformations, with a commitment to addressing unmet medical needs in this area [1][9] Group 1: QTORIN™ Rapamycin Development - QTORIN™ rapamycin is a single-phase anhydrous gel designed to enhance dermal bioavailability and overcome challenges related to crystallization and stability of rapamycin [1][2] - The Phase 3 SELVA study demonstrated that QTORIN™ rapamycin met its primary endpoint with statistically significant improvement in the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) (p<0.001) [4] - QTORIN™ rapamycin is being developed for multiple conditions, including microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, with a fourth indication expected to be announced in the second half of 2026 [5][9] Group 2: Porokeratosis Research - A qualitative study highlighted the significant burden of living with porokeratosis, a rare genetic skin disease with no FDA-approved therapies, emphasizing its physical, psychosocial, and cancer-related impacts [2][12] - The study involved ten in-depth interviews with patients and caregivers, revealing challenges such as social isolation, anxiety, and limitations in daily activities due to the disease [12] - Palvella is also developing QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis, with a Phase 2 trial anticipated to begin in the second half of 2026 [8]